Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
Breast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1332539/full |
| _version_ | 1797338738185994240 |
|---|---|
| author | Yan Liang Yan Liang Purong Zhang Feng Li Feng Li Houyun Lai Houyun Lai Tingting Qi Yixin Wang |
| author_facet | Yan Liang Yan Liang Purong Zhang Feng Li Feng Li Houyun Lai Houyun Lai Tingting Qi Yixin Wang |
| author_sort | Yan Liang |
| collection | DOAJ |
| description | Breast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effectively merge the specificity of antibodies with the cytotoxicity of chemotherapeutic agents, offering a novel strategy for precision treatment of breast cancer. Notably, trastuzumab emtansine (T-DM1) has provided a new therapeutic option for HER2-positive breast cancer patients globally, especially those resistant to conventional treatments. The development of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) has further broadened the applicability of ADCs in breast cancer therapy, presenting new hopes for patients with low HER2 expression and triple-negative breast cancer. However, the application of ADCs presents certain challenges. For instance, their treatment may lead to adverse reactions such as interstitial lung disease, thrombocytopenia, and diarrhea. Moreover, prolonged treatment could result in ADCs resistance, complicating the therapeutic process. Economically, the high costs of ADCs might hinder their accessibility in low-income regions. This article reviews the structure, mechanism of action, and clinical trials of commercially available ADCs for breast cancer treatment, with a focus on the clinical trials of the three drugs, aiming to provide insights for clinical applications and future research. |
| first_indexed | 2024-03-08T09:35:38Z |
| format | Article |
| id | doaj.art-3d73ec91e9ba4f5a8134fbb39a0295b6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T09:35:38Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3d73ec91e9ba4f5a8134fbb39a0295b62024-01-30T09:38:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-01-011410.3389/fphar.2023.13325391332539Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancerYan Liang0Yan Liang1Purong Zhang2Feng Li3Feng Li4Houyun Lai5Houyun Lai6Tingting Qi7Yixin Wang8Sichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaSichuan Cancer Hospital, Cancer Hospital Affiliate University of Electronic Science and Technology, Chengdu, ChinaBreast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effectively merge the specificity of antibodies with the cytotoxicity of chemotherapeutic agents, offering a novel strategy for precision treatment of breast cancer. Notably, trastuzumab emtansine (T-DM1) has provided a new therapeutic option for HER2-positive breast cancer patients globally, especially those resistant to conventional treatments. The development of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) has further broadened the applicability of ADCs in breast cancer therapy, presenting new hopes for patients with low HER2 expression and triple-negative breast cancer. However, the application of ADCs presents certain challenges. For instance, their treatment may lead to adverse reactions such as interstitial lung disease, thrombocytopenia, and diarrhea. Moreover, prolonged treatment could result in ADCs resistance, complicating the therapeutic process. Economically, the high costs of ADCs might hinder their accessibility in low-income regions. This article reviews the structure, mechanism of action, and clinical trials of commercially available ADCs for breast cancer treatment, with a focus on the clinical trials of the three drugs, aiming to provide insights for clinical applications and future research.https://www.frontiersin.org/articles/10.3389/fphar.2023.1332539/fullbreast cancerT-DM1T-DXdSGADC |
| spellingShingle | Yan Liang Yan Liang Purong Zhang Feng Li Feng Li Houyun Lai Houyun Lai Tingting Qi Yixin Wang Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer Frontiers in Pharmacology breast cancer T-DM1 T-DXd SG ADC |
| title | Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer |
| title_full | Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer |
| title_fullStr | Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer |
| title_full_unstemmed | Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer |
| title_short | Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer |
| title_sort | advances in the study of marketed antibody drug conjugates adcs for the treatment of breast cancer |
| topic | breast cancer T-DM1 T-DXd SG ADC |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1332539/full |
| work_keys_str_mv | AT yanliang advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT yanliang advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT purongzhang advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT fengli advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT fengli advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT houyunlai advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT houyunlai advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT tingtingqi advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer AT yixinwang advancesinthestudyofmarketedantibodydrugconjugatesadcsforthetreatmentofbreastcancer |